Moderna to Provide Business and Pipeline Updates at the 2020 J.P. Morgan Healthcare Conference
January 06 2020 - 8:30AM
Business Wire
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines
to create a new generation of transformative medicines for
patients, today announced that CEO Stéphane Bancel will present an
update on the Company and its pipeline of mRNA development programs
at this year’s 38th annual J.P. Morgan Healthcare Conference.
Mr. Bancel’s presentation will take place on Monday, January 13,
2020 at 4:30 p.m. PT in the Colonial Room at The Westin St. Francis
Hotel in San Francisco. The presentation will be followed by a
question and answer session. A live webcast of both the
presentation and question and answer session will be available
under “Events & Presentations” in the investors section of
Moderna’s website at https://investors.modernatx.com/. A replay of
the webcast will be archived on Moderna’s website for 30 days
following the presentation.
About Moderna
Moderna is advancing messenger RNA (mRNA) science to create a
new class of transformative medicines for patients. mRNA medicines
are designed to direct the body’s cells to produce intracellular,
membrane or secreted proteins that have a therapeutic or preventive
benefit with the potential to address a broad spectrum of diseases.
Moderna’s platform builds on continuous advances in basic and
applied mRNA science, delivery technology and manufacturing,
providing the Company the capability to pursue in parallel a robust
pipeline of new development candidates. Moderna is developing
therapeutics and vaccines for infectious diseases, immuno-oncology,
rare diseases and cardiovascular diseases, independently and with
strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has
strategic alliances for development programs with AstraZeneca, Plc.
and Merck, Inc., as well as the Defense Advanced Research Projects
Agency (DARPA), an agency of the U.S. Department of Defense and the
Biomedical Advanced Research and Development Authority (BARDA), a
division of the Office of the Assistant Secretary for Preparedness
and Response (ASPR) within the U.S. Department of Health and Human
Services (HHS). Moderna has been named a top employer by Science
for the fifth year in a row. To learn more, visit
www.modernatx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200106005539/en/
Investors: Lavina Talukdar Head of Investor Relations
617-209-5834 Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024